TrialSignal
Clinical trial intelligence report
A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04769050
Status
UNKNOWN
Phase
N/A
Sponsor
Fudan University
Executive brief
Investment-Ready Snapshot
Dynamic observationaL study with PET of 68Ga-HER2-affibody in anti-HER2 treatment
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04769050
Indication
Breast Cancer
Modality
monoclonal antibody
Target
Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.
Intervention
Docetaxel combined with Trastuzumab±Pertuzumab, T-DM1 or Capecitabine combined with Pyrotinib regimen.
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.